252 related articles for article (PubMed ID: 26608413)
1. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer.
Elbasateeny SS; Salem AA; Abdelsalam WA; Salem RA
Pathol Res Pract; 2016 Jan; 212(1):10-6. PubMed ID: 26608413
[TBL] [Abstract][Full Text] [Related]
2. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
5. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
7. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
8. Detection of putative stem cell markers, CD44/CD133, in primary and lymph node metastases in head and neck squamous cell carcinomas. A preliminary immunohistochemical and in vitro study.
Mannelli G; Magnelli L; Deganello A; Busoni M; Meccariello G; Parrinello G; Gallo O
Clin Otolaryngol; 2015 Aug; 40(4):312-20. PubMed ID: 25641707
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
Huang X; Sheng Y; Guan M
Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
[TBL] [Abstract][Full Text] [Related]
11. The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC).
Mărgăritescu C; Pirici D; Simionescu C; Stepan A
Rom J Morphol Embryol; 2011; 52(3 Suppl):985-93. PubMed ID: 22119814
[TBL] [Abstract][Full Text] [Related]
12. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
13. CD133+CD44+ population efficiently enriches colon cancer initiating cells.
Haraguchi N; Ohkuma M; Sakashita H; Matsuzaki S; Tanaka F; Mimori K; Kamohara Y; Inoue H; Mori M
Ann Surg Oncol; 2008 Oct; 15(10):2927-33. PubMed ID: 18663533
[TBL] [Abstract][Full Text] [Related]
14. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis.
Bellizzi A; Sebastian S; Ceglia P; Centonze M; Divella R; Manzillo EF; Azzariti A; Silvestris N; Montemurro S; Caliandro C; De Luca R; Cicero G; Rizzo S; Russo A; Quaranta M; Simone G; Paradiso A
J Cell Physiol; 2013 Feb; 228(2):408-15. PubMed ID: 22740326
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice.
Dou J; He XF; Cao WH; Zhao FS; Wang XY; Liu YR; Wang J
Cell Mol Biol (Noisy-le-grand); 2013 Oct; Suppl 59():OL1861-8. PubMed ID: 24120113
[TBL] [Abstract][Full Text] [Related]
18. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.
Wakamatsu Y; Sakamoto N; Oo HZ; Naito Y; Uraoka N; Anami K; Sentani K; Oue N; Yasui W
Pathol Int; 2012 Feb; 62(2):112-9. PubMed ID: 22243781
[TBL] [Abstract][Full Text] [Related]
19. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
20. CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
